Drug intelligence / Profile preview

TH-CART-027

Development stage: Phase 1
Lead developer: ThinkingBiomed
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

TH-CART-027 is an investigational CAR-T cell therapy designed to target CD276 (also known as B7-H3), a protein frequently overexpressed in various cancers. As a **chimeric antigen receptor T cell therapy**, TH-CART-027 involves genetically engineering a patient's own T cells to express a receptor that enables selective binding and cytotoxicity against CD276-expressing tumor cells. The therapy is under study for its potential antitumor activity, safety, and tolerability, with early-stage clinical trials initiated to evaluate its use in solid tumors. The drug is developed by ThinkingBiomed.

Other names: TH027 CAR-TTH-027 CAR-TTH 027 CAR-TTH-027TH027TH 027

Targets

B7-H3

Beyond the preview

Go deeper on TH-CART-027.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TH-CART-027.

Explore the full profile